Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-08-18 Sale | 2026-08-20 4:10 pm | Keros Therapeutics Inc. | KROS | Tanini Annita Corp. Controller & VP, Finance | 1,224 | $10.29 | $12,595 | 45,144 (Direct) | View |
| 2026-08-18 Sale | 2026-08-20 4:10 pm | Keros Therapeutics Inc. | KROS | Lerner Lorena Raquel Chief Scientific Officer | 3,568 | $10.29 | $36,715 | 27,559 (Direct) | View |
| 2026-08-18 Sale | 2026-08-20 4:10 pm | Keros Therapeutics Inc. | KROS | Cho Esther Chief Legal Officer | 4,485 | $10.29 | $46,151 | 35,770 (Direct) | View |
| 2026-08-18 Sale | 2026-08-20 4:10 pm | Keros Therapeutics Inc. | KROS | Newton Charles W. Director | 551 | $10.3 | $5,675 | 12,114 (Direct) | View |
| 2026-08-17 Purchase | 2026-08-19 4:10 pm | Keros Therapeutics Inc. | KROS | BIENAIME JEAN JACQUES Director | 1,000 | $10.27 | $10,270 | 19,592 (Direct) | View |
| 2026-07-15 Purchase | 2026-07-17 4:10 pm | Keros Therapeutics Inc. | KROS | BIENAIME JEAN JACQUES Director | 1,000 | $10.61 | $10,610 | 18,592 (Direct) | View |
| 2026-06-15 Purchase | 2026-06-17 4:55 pm | Keros Therapeutics Inc. | KROS | BIENAIME JEAN JACQUES Director | 1,000 | $10.19 | $10,190 | 17,592 (Direct) | View |
| 2026-06-11 Sale | 2026-06-15 4:15 pm | Keros Therapeutics Inc. | KROS | Newton Charles W. Director | 550 | $10.04 | $5,522 | 12,665 (Direct) | View |
| 2026-06-04 Sale | 2026-06-08 4:37 pm | Keros Therapeutics Inc. | KROS | Farzan Nima Director | 2,625 | $10.73 | $28,166 | 9,767 (Direct) | View |
| 2026-06-04 Sale | 2026-06-08 4:36 pm | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 2,625 | $10.73 | $28,166 | 263,238 (Indirect Direct) | View |
| 2026-06-04 Sale | 2026-06-05 4:15 pm | Keros Therapeutics Inc. | KROS | Seth Alpna Director | 2,625 | $10.72 | $28,140 | 9,767 (Direct) | View |
| 2026-05-15 Purchase | 2026-05-19 4:15 pm | Keros Therapeutics Inc. | KROS | BIENAIME JEAN JACQUES Director | 1,000 | $10.58 | $10,580 | 9,450 (Direct) | View |
| 2026-04-15 Purchase | 2026-04-17 4:15 pm | Keros Therapeutics Inc. | KROS | BIENAIME JEAN JACQUES Director | 1,000 | $11.7 | $11,700 | 8,450 (Direct) | View |
| 2026-03-09 Purchase | 2026-03-11 4:33 pm | Keros Therapeutics Inc. | KROS | BIENAIME JEAN JACQUES Director | 2,000 | $11.21 | $22,420 | 7,450 (Direct) | View |
| 2026-02-19 Sale | 2026-02-20 4:15 pm | Keros Therapeutics Inc. | KROS | Seehra Jasbir CHIEF EXECUTIVE OFFICER | 7,015 | $16.17 | $113,433 | 385,708 (Direct) | View |
| 2026-02-18 Sale | 2026-02-20 4:15 pm | Keros Therapeutics Inc. | KROS | Lerner Lorena Raquel Chief Science Officer | 3,873 | $16.35 | $63,324 | 31,127 (Direct) | View |
| 2026-02-18 Sale | 2026-02-20 4:15 pm | Keros Therapeutics Inc. | KROS | Cho Esther SVP, General Counsel | 4,745 | $16.35 | $77,581 | 39,755 (Direct) | View |
| 2026-02-18 Sale | 2026-02-20 4:15 pm | Keros Therapeutics Inc. | KROS | Regnante Keith CHIEF FINANCIAL OFFICER | 4,739 | $16.35 | $77,483 | 39,261 (Direct) | View |
| 2025-11-21 Sale | 2025-12-18 4:34 pm | Keros Therapeutics Inc. | KROS | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director | 214,522 | $17.75 | $3,807,766 | 45,057 (Indirect) | View |
| 2025-11-21 Sale | 2025-12-18 4:27 pm | Keros Therapeutics Inc. | KROS | GORDON CARL L Director | 214,522 | $17.75 | $3,807,766 | 45,057 (Indirect) | View |
| 2025-11-21 Sale | 2025-12-18 4:15 pm | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 322,021 | $17.75 | $5,715,873 | 108,674 (Indirect Direct) | View |
| 2025-10-15 Sale | 2025-10-17 5:53 pm | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. Kariv Tomer Nussbaum Ran 10% Owner | 4,787,331 | $17.75 | $84,975,125 | 10,500 (Indirect) | View |
| 2025-10-15 Sale | 2025-10-15 1:24 pm | Keros Therapeutics Inc. | KROS | ADAR1 Capital Management LLC ADAR1 Partners LP ADAR1 Capital Management GP LLC Schneeberger Daniel 10% Owner | 5,389,264 | $17.75 | $95,659,436 | 0 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
Ownership | 2026-08-13 4:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Tanini Annita Corp. Controller & VP, Finance | 0 | $0 | 117,468 (Direct) | View |
| 2026-07-01 Option Award | 2026-07-06 4:31 pm | N/A 2036-06-30 | Keros Therapeutics Inc. | KROS | Prener Anne Director | 28,656 | $0 | 28,656 (Direct) | View |
| 2026-06-03 Option Award | 2026-06-05 5:20 pm | N/A 2036-06-02 | Keros Therapeutics Inc. | KROS | Seth Alpna Director | 14,575 | $0 | 19,825 (Direct) | View |
| 2026-06-03 Option Award | 2026-06-05 4:15 pm | N/A 2036-06-02 | Keros Therapeutics Inc. | KROS | GRAY MARY ANN Director | 14,575 | $0 | 19,825 (Direct) | View |
| 2026-06-03 Option Award | 2026-06-05 4:15 pm | N/A 2036-06-02 | Keros Therapeutics Inc. | KROS | Farzan Nima Director | 14,575 | $0 | 19,825 (Direct) | View |
| 2026-06-03 Option Award | 2026-06-05 4:15 pm | N/A 2036-06-02 | Keros Therapeutics Inc. | KROS | BIENAIME JEAN JACQUES Director | 14,575 | $0 | 24,025 (Direct) | View |
| 2026-06-03 Option Award | 2026-06-05 4:15 pm | N/A 2036-06-02 | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 14,575 | $0 | 273,296 (Direct) | View |
| 2026-04-02 Exercise | 2026-04-06 4:15 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Seehra Jasbir CHIEF EXECUTIVE OFFICER | 55,000 | $0.3 | 638,152 (Direct) | View |
| 2026-04-02 Exercise | 2026-04-06 4:15 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Seehra Jasbir CHIEF EXECUTIVE OFFICER | 55,000 | $0 | 638,152 (Direct) | View |
| 2026-02-24 Option Award(A) | 2026-03-27 4:15 pm | N/A 2036-02-23 | Keros Therapeutics Inc. | KROS | Cho Esther Chief Legal Officer | 80,000 | $0 | 80,000 (Direct) | View |
| 2026-03-09 Option Award | 2026-03-11 4:39 pm | N/A 2036-03-08 | Keros Therapeutics Inc. | KROS | Newton Charles W. Director | 28,003 | $0 | 28,003 (Direct) | View |
| 2026-02-24 Option Award | 2026-02-26 4:15 pm | N/A 2036-02-23 | Keros Therapeutics Inc. | KROS | Seehra Jasbir CHIEF EXECUTIVE OFFICER | 317,000 | $0 | 317,000 (Direct) | View |
| 2026-02-24 Option Award | 2026-02-26 4:15 pm | N/A 2036-02-23 | Keros Therapeutics Inc. | KROS | Regnante Keith CHIEF FINANCIAL OFFICER | 60,000 | $0 | 60,000 (Direct) | View |
| 2026-02-24 Option Award | 2026-02-26 4:15 pm | N/A 2036-02-23 | Keros Therapeutics Inc. | KROS | Cho Esther Chief Legal Officer | 80,000 | $0 | 80,000 (Direct) | View |
| 2026-02-24 Option Award | 2026-02-26 4:15 pm | N/A 2036-02-23 | Keros Therapeutics Inc. | KROS | Lerner Lorena Raquel Chief Scientific Officer | 75,000 | $0 | 75,000 (Direct) | View |
| 2026-01-07 Option Award | 2026-01-09 4:15 pm | N/A 2034-02-22 | Keros Therapeutics Inc. | KROS | Seehra Jasbir CHIEF EXECUTIVE OFFICER | 62,500 | $0 | 62,500 (Direct) | View |